Literature DB >> 21040831

Adaptive immunity to the hepatitis C virus.

Christopher M Walker1.   

Abstract

The hepatitis C virus (HCV) is a global public health problem affecting approximately 2% of the human population. The majority of HCV infections (more than 70%) result in life-long persistence of the virus that substantially increases the risk of serious liver diseases, including cirrhosis and hepatocellular carcinoma. The remainder (less than 30%) resolves spontaneously, often resulting in long-lived protection from persistence upon reexposure to the virus. To persist, the virus must replicate and this requires effective evasion of adaptive immune responses. In this review, the role of humoral and cellular immunity in preventing HCV persistence, and the mechanisms used by the virus to subvert protective host responses, are considered.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21040831      PMCID: PMC6171124          DOI: 10.1016/B978-0-12-385032-4.00002-1

Source DB:  PubMed          Journal:  Adv Virus Res        ISSN: 0065-3527            Impact factor:   9.937


  286 in total

1.  Liver-derived CTL in hepatitis C virus infection: breadth and specificity of responses in a cohort of persons with chronic infection.

Authors:  D K Wong; D D Dudley; N H Afdhal; J Dienstag; C M Rice; L Wang; M Houghton; B D Walker; M J Koziel
Journal:  J Immunol       Date:  1998-02-01       Impact factor: 5.422

2.  T cells with a CD4+CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection.

Authors:  Tobias Boettler; Hans Christian Spangenberg; Christoph Neumann-Haefelin; Elisabeth Panther; Simonetta Urbani; Carlo Ferrari; Hubert E Blum; Fritz von Weizsäcker; Robert Thimme
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

3.  The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies.

Authors:  P Farci; A Shimoda; A Coiana; G Diaz; G Peddis; J C Melpolder; A Strazzera; D Y Chien; S J Munoz; A Balestrieri; R H Purcell; H J Alter
Journal:  Science       Date:  2000-04-14       Impact factor: 47.728

4.  A point mutation leading to hepatitis C virus escape from neutralization by a monoclonal antibody to a conserved conformational epitope.

Authors:  Zhen-Yong Keck; Oakley Olson; Meital Gal-Tanamy; Jinming Xia; Arvind H Patel; Marlène Dreux; Francois-Loïc Cosset; Stanley M Lemon; Steven K H Foung
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

5.  Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: effect of viremia levels and antiviral treatment.

Authors:  Simona Urbani; Barbara Amadei; Daniela Tola; Giuseppe Pedrazzi; Luca Sacchelli; Maria Cristina Cavallo; Alessandra Orlandini; Gabriele Missale; Carlo Ferrari
Journal:  J Hepatol       Date:  2008-01-28       Impact factor: 25.083

6.  Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection.

Authors:  Kimberly Page; Judith A Hahn; Jennifer Evans; Stephen Shiboski; Paula Lum; Eric Delwart; Leslie Tobler; William Andrews; Lia Avanesyan; Stewart Cooper; Michael P Busch
Journal:  J Infect Dis       Date:  2009-10-15       Impact factor: 5.226

7.  Characterization of functional hepatitis C virus envelope glycoproteins.

Authors:  Anne Op De Beeck; Cécile Voisset; Birke Bartosch; Yann Ciczora; Laurence Cocquerel; Zhenyong Keck; Steven Foung; François-Loïc Cosset; Jean Dubuisson
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

8.  Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33.

Authors:  Alexander W Tarr; Ania M Owsianka; Dhanya Jayaraj; Richard J P Brown; Timothy P Hickling; William L Irving; Arvind H Patel; Jonathan K Ball
Journal:  J Gen Virol       Date:  2007-11       Impact factor: 3.891

9.  Analysis of successful immune responses in persons infected with hepatitis C virus.

Authors:  F Lechner; D K Wong; P R Dunbar; R Chapman; R T Chung; P Dohrenwend; G Robbins; R Phillips; P Klenerman; B D Walker
Journal:  J Exp Med       Date:  2000-05-01       Impact factor: 14.307

10.  Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33.

Authors:  Alexander W Tarr; Ania M Owsianka; Judith M Timms; C Patrick McClure; Richard J P Brown; Timothy P Hickling; Thomas Pietschmann; Ralf Bartenschlager; Arvind H Patel; Jonathan K Ball
Journal:  Hepatology       Date:  2006-03       Impact factor: 17.425

View more
  36 in total

1.  Human leukocyte antigen B27 selects for rare escape mutations that significantly impair hepatitis C virus replication and require compensatory mutations.

Authors:  Christoph Neumann-Haefelin; Cesar Oniangue-Ndza; Thomas Kuntzen; Julia Schmidt; Katja Nitschke; John Sidney; Célia Caillet-Saguy; Marco Binder; Nadine Kersting; Michael W Kemper; Karen A Power; Susan Ingber; Laura L Reyor; Kelsey Hills-Evans; Arthur Y Kim; Georg M Lauer; Volker Lohmann; Alessandro Sette; Matthew R Henn; Stéphane Bressanelli; Robert Thimme; Todd M Allen
Journal:  Hepatology       Date:  2011-10       Impact factor: 17.425

2.  Will there be a vaccine to protect against the hepatitis C virus?

Authors:  Benoît Callendret; Christopher M Walker
Journal:  Gastroenterology       Date:  2012-05       Impact factor: 22.682

3.  The proportion of different interleukin-17-producing T-cell subsets is associated with liver fibrosis in chronic hepatitis C.

Authors:  Fabio C O F Cachem; Aleida S Dias; Clarice Monteiro; José Roberto Castro; Gabriel Fernandes; Letícia Delphim; Adilson J Almeida; Felipe Tavares; Alessandra M A Maciel; Marcia M Amendola-Pires; Carlos E Brandão-Mello; Cleonice A M Bento
Journal:  Immunology       Date:  2017-03-13       Impact factor: 7.397

4.  Fueling fibrosis in chronic hepatitis C.

Authors:  Ramon Bataller; Stanley M Lemon
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-27       Impact factor: 11.205

5.  Tim-3 pathway controls regulatory and effector T cell balance during hepatitis C virus infection.

Authors:  Jonathan P Moorman; Jia M Wang; Ying Zhang; Xiao J Ji; Cheng J Ma; Xiao Y Wu; Zhan S Jia; Ke S Wang; Zhi Q Yao
Journal:  J Immunol       Date:  2012-06-15       Impact factor: 5.422

6.  Profibrogenic chemokines and viral evolution predict rapid progression of hepatitis C to cirrhosis.

Authors:  Patrizia Farci; Kurt Wollenberg; Giacomo Diaz; Ronald E Engle; Maria Eliana Lai; Paul Klenerman; Robert H Purcell; Oliver G Pybus; Harvey J Alter
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-24       Impact factor: 11.205

Review 7.  The yin and yang of hepatitis C: synthesis and decay of hepatitis C virus RNA.

Authors:  You Li; Daisuke Yamane; Takahiro Masaki; Stanley M Lemon
Journal:  Nat Rev Microbiol       Date:  2015-08-10       Impact factor: 60.633

8.  Evolution of a cell culture-derived genotype 1a hepatitis C virus (H77S.2) during persistent infection with chronic hepatitis in a chimpanzee.

Authors:  MinKyung Yi; Fengyu Hu; Michael Joyce; Vikas Saxena; Christoph Welsch; Deborah Chavez; Bernadette Guerra; Daisuke Yamane; Ronald Veselenak; Rick Pyles; Christopher M Walker; Lorne Tyrrell; Nigel Bourne; Robert E Lanford; Stanley M Lemon
Journal:  J Virol       Date:  2014-01-15       Impact factor: 5.103

9.  Signatures of protective memory immune responses during hepatitis C virus reinfection.

Authors:  Mohamed S Abdel-Hakeem; Nathalie Bédard; Donald Murphy; Julie Bruneau; Naglaa H Shoukry
Journal:  Gastroenterology       Date:  2014-07-16       Impact factor: 22.682

10.  KLRG1 negatively regulates natural killer cell functions through the Akt pathway in individuals with chronic hepatitis C virus infection.

Authors:  Jia M Wang; Yong Q Cheng; Lei Shi; Ruo S Ying; Xiao Y Wu; Guang Y Li; Jonathan P Moorman; Zhi Q Yao
Journal:  J Virol       Date:  2013-08-21       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.